Astefor (Levofloxacin) is a systemic anti-infective used to provide bacterial clearance in several serious clinical situations, which supports a reduction in the patient's overall symptom burden. It is commonly used to help manage severe infections across multiple body systems.

The medication is primarily applied in settings involving acute or disruptive symptom patterns from bacterial infections of the lungs (such as community-acquired pneumonia and acute exacerbations of chronic bronchitis), the genitourinary tract (including complicated UTIs and acute pyelonephritis), and the skin/soft tissues (like complicated cellulitis). It is also used for specific high-risk conditions, including the management of Inhalational Anthrax or Plague.

“The use of Astefor is relevant in contexts marked by increased discomfort or tension, particularly when symptoms related to inflammation and fever intensify.”

Astefor is applied in addressing symptom clusters that may become intense or disruptive, including severe cough, fever, painful urination (dysuria), and localized inflammation. The core benefit is that by addressing the underlying cause, it assists with symptom relief, which supports patients during difficult episodes by easing distress and helping maintain a sense of stability when symptoms are more noticeable.

Quick Fact	Relief for
Assists with symptoms that interfere with normal breathing	Symptoms of acute pneumonia and chronic bronchitis exacerbations
Helps maintain stability	Genitourinary pain and systemic fever

Regulatory References

1. NIH MedlinePlus overview of Levofloxacin uses

Who Can and Cannot Use Astefor (Levofloxacin)?

Astefor (Levofloxacin) eligibility is strictly defined by regulatory guidelines and is not suitable for all populations. Use is contraindicated in patients with a history of hypersensitivity to levofloxacin or other quinolone anti-infectives, as well as those with epilepsy or a history of tendon disorders related to previous fluoroquinolone use. Use is also contraindicated during pregnancy and breastfeeding.

Age and Condition Restrictions

Population Group	Eligibility Status	Restriction/Conditional Use
Adults (≥18 years)	Standard Eligible Population	Must be reserved for some infections if alternatives are available.
Children/Adolescents (<18 years)	Contraindicated	Prohibited for standard use, with specific exceptions only for conditions like Plague or Anthrax.
Renal Impairment	Conditional Eligibility	Requires dose adjustment for patients with reduced kidney function (CrCl < 50 mL/min).
Older Adults (≥60 years)	Caution Required	Increased risk of tendon disorders; use requires special caution.

Patients with known factors for QT prolongation (such as uncorrected hypokalemia) or those taking corticosteroids require special caution, as these conditions are associated with heightened risk. The safety and effectiveness of Astefor have not been established in infants under six months of age.

The official regulatory profile for Astefor (Levofloxacin) is structured around documented interactions that alter absorption, affect systemic clearance, or involve additive pharmacodynamic risks.

Official Interaction Statements:

• Absorption Interference: The oral tablet's absorption is significantly decreased by chelation with multivalent cation-containing products, including antacids (magnesium- or aluminium-containing), Sucralfate, iron or zinc salts, and buffered Didanosine formulations. A mandatory constraint requires these products to be administered at least two hours before or after Levofloxacin to maintain bioavailability. The intravenous formulation must not be co-administered in the same IV line with any multivalent cations.
• Systemic Exposure: Co-administration with Probenecid and Cimetidine reduces Levofloxacin renal clearance by inhibiting tubular secretion, resulting in officially stated increases in systemic exposure. Levofloxacin also increases the half-life of Ciclosporin by 33%.
• Pharmacodynamic Risk: Levofloxacin poses an additive risk of QT interval prolongation when combined with other QT-prolonging drugs, making this combination restricted. Furthermore, the effect of Vitamin K Antagonists (e.g., Warfarin) may be enhanced, increasing the risk of bleeding. Co-administration with NSAIDs is documented to increase the risk of central nervous system excitation, and with antidiabetic agents, it carries a risk of blood glucose disturbances.

Connection to the overall interaction profile:

Regulatory documents define the product’s interaction structure by establishing mandatory timing separation rules for products containing metal cations and by restricting the use of products that create an additive risk for serious outcomes, such as QT prolongation. The profile also formally documents altered clearance pathways for Levofloxacin when combined with specific renal tubular secretion inhibitors.

Dual Targeting of Essential Bacterial Enzymes

Levofloxacin initiates its action by acting as a dual inhibitor of the bacterial enzymes DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are necessary for bacterial DNA maintenance, replication, and separation during cell division. By binding to the DNA-enzyme complex, the drug physically traps the enzymes, preventing them from performing their essential functions.

---

Bactericidal Cascade via DNA Integrity Disruption

This molecular binding leads to the rapid introduction of irreversible double-strand breaks (DSBs) in the bacterial DNA. This extensive genetic damage and subsequent blockade of DNA replication triggers a bactericidal cascade, actively forcing the bacterial cell into programmed death. The resulting destruction of susceptible organisms is the core physiological consequence of the mechanism.

---

Resistance Mechanism Constraints

The mechanism's function is constrained by bacterial counter-adaptations, such as genetic mutations in the genes encoding the target enzymes and the expression of efflux pumps. These limitations either reduce the drug's binding affinity or lower its effective intracellular concentration, which attenuates the bactericidal action.

Official Administration Guidelines: Astefor (Levofloxacin)

Astefor, containing Levofloxacin, is administered via oral (tablets or solution), intravenous (IV) infusion, or topical (ophthalmic solution) routes, according to the prescribed regimen. The treatment course requires strict adherence to official dosing and timing instructions.

---

Administration Detail	Official Instruction Summary
Standard Dosing	Adults receive a dose of 250 mg to 750 mg once daily (every 24 hours), depending on the specific regimen. Typical course durations range from 3 days (for some uncomplicated infections) to 60 days (for specific high-risk exposures).
Oral Intake Rules	Tablets may be taken with or without food. The oral solution should be taken 1 hour before or 2 hours after eating.
Drug Timing Constraint	Oral forms must be administered at least two hours before or after products containing multivalent cations, such as antacids, sucralfate, iron, or zinc salts, to ensure proper absorption.
IV Infusion Method	Intravenous administration must be by slow infusion only. A 250 mg dose requires infusion over at least 30 minutes, and doses of 500 mg or 750 mg must be infused over at least 60 or 90 minutes, respectively, to avoid rapid delivery.
Dose Adjustment	Dose modification is mandatory for adult patients with renal impairment (creatinine clearance < 50 mL/ min). No general adjustment is necessary for older adults unless reduced renal function is present, and no adjustment is required for hepatic impairment.
Sequential Therapy	The IV and oral routes are considered interchangeable in terms of dosage, allowing for a switch from intravenous to oral administration at the same dose once the patient’s condition permits.

---

If an oral dose is missed, it should be taken as soon as it is remembered, provided it is not almost time for the next scheduled dose, in which case the missed dose should be skipped. The entire prescribed treatment duration must be completed as directed.

Research Evidence / Overview of Studies for Astefor (ANTIBACTERIALS)

---

Evidence for Use in Lower Respiratory Tract Infections (LRTIs)

Research has studied Astefor primarily through short-term randomized controlled trials (RCTs) and systematic reviews, comparing it to an active comparator or a placebo. These studies monitored outcomes related to physical discomfort and overall well-being in non-hospitalized and hospitalized adults and defined pediatric subgroups with mild to moderate infections. Findings describe patterns observed related to clinical symptom changes, such as fever and cough, and measurements of hospital stay duration. Some comparative trials reported measurements of the time patients took to achieve clinical stability.

---

Evidence for Use in Urinary Tract Infections (UTIs)

Astefor was evaluated in studies examining how symptoms evolved in conditions characterized by acute changes, specifically uncomplicated urinary tract infections. The study designs involved randomized and non-randomized approaches, mainly focusing on defined adult and pediatric subgroups. Trial reports documented the proportion of participants who reported changes in typical UTI symptoms and monitored specific percentages for the eradication of key susceptible bacterial strains at the post-treatment assessment. Research also describes patterns in the observed rates of infection recurrence during a limited follow-up period.

---

Evidence for Use in Skin and Skin Structure Infections (SSTIs)

Research examined Astefor for mild-to-moderate skin and skin structure infections. Studies monitored outcomes related to physical discomfort, such as the overall change in infection severity (e.g., reduction in swelling or redness), and the continued presence of infection-causing organisms at follow-up. Findings generally apply only to the populations studied, which were primarily those with mild to moderate infections caused by specific, susceptible bacterial types.

---

What Is Still Uncertain About Astefor (ANTIBACTERIALS) Research

Evidence highlights what is known—and what is still uncertain—about this antibacterial. A key research limitation is the scarcity of long-term evidence needed to fully establish sustained patient outcomes. Follow-up durations were limited in the main body of evidence. Comparative evidence is lacking in some areas, meaning direct comparisons with all other relevant antibacterial options are not consistently available across all indications. Data are also limited for specific patient groups, such as those with severe underlying co-morbidities.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE) Guideline: Urinary tract infection (UTI) in under 16s: diagnosis and management (Used for Pediatric UTI context)

Common questions about Astefor (ANTIBACTERIALS) (FAQ)

Q: What is Astefor?

Astefor is a medication that contains Aztreonam. It belongs to a class of antibiotics known as monobactams.

It is used to treat serious infections caused by specific types of bacteria. These can include infections of the:

• Urinary tract
• Lower respiratory tract (like pneumonia)
• Skin and skin structure
• Intra-abdominal area (like peritonitis)
• Blood (septicemia)

Astefor is often reserved for treating infections caused by aerobic Gram-negative bacteria, especially in people who are allergic to penicillin or cephalosporin antibiotics.

---

Q: How is Astefor typically administered?

Astefor is usually administered as an injection into a vein (intravenous or IV) or into a large muscle (intramuscular or IM). The specific method of administration, dose, and frequency are determined by a healthcare provider based on the type and severity of the infection, and the patient's kidney function.

It is not available in a tablet or capsule form for oral use. It must be administered in a healthcare setting or by a trained professional.

---

Q: What are the potential side effects of Astefor?

Like all medicines, Astefor can cause side effects, although not everyone gets them. Common side effects may include:

• Local reactions at the injection site (pain, swelling, redness).
• Gastrointestinal issues such as nausea, vomiting, or diarrhea.
• Changes in blood tests (elevated liver enzymes).
• Rash or itching.

Serious side effects can occur, though they are less common, and may include:

• Severe allergic reactions (anaphylaxis), which can cause difficulty breathing or swelling of the face, lips, or throat.
• Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to life-threatening colitis.

Patients should inform their healthcare provider immediately if they experience any signs of a serious reaction.

---

Q: Can Astefor be used if a person has a penicillin allergy?

Yes, Astefor (Aztreonam) is often a suitable option for people with a penicillin allergy or an allergy to cephalosporins.

Astefor belongs to a different class of antibiotics (monobactams) and has a distinct chemical structure. It generally does not cause the same allergic reactions as penicillins and cephalosporins. However, patients should always inform their healthcare provider about all their known allergies before starting any new antibiotic treatment.

How to Store and Dispose of Astefor (ANTIBACTERIALS)

Official regulatory guidelines require Astefor (Levofloxacin) to be stored at Controlled Room Temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF). The product must be kept in its original container and be protected from light and moisture.

It is mandatory to avoid excessive heat and to protect the solution for infusion from freezing to maintain its stability. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Astefor must be disposed of safely. The preferred method is through an authorized drug take-back program. If household disposal is necessary, the medicine should be mixed with an unappealing substance (like dirt or used coffee grounds) and sealed in a bag before being placed in the trash. Do not flush the medication down the sink or toilet.